Methodhub Software Ltd. IPO Allotment Status: Check Overall Subscription & Steps to Verify Status 

The allotment for the Methodhub Software Ltd. IPO is expected to be finalised today, December 10, 2025. The IPO bidding opened on December 5, 2025, and closed yesterday, December 9, 2025. The Methodhub Software Ltd. IPO will list on BSE SME with the tentative listing date finalised as December 12, 2025. 

This is a book build issue of ₹103.02 crores, combining a fresh issue of 0.45 crore shares and an offer-for-sale of 0.08 crore shares.

Check the Methodhub Software Ltd. IPO Allotment Status on NSE, BSE and the registrar’s website. 

Procedure to Check Methodhub Software Ltd. IPO Allotment Status Online On BSE

• Click here to visit the application status page. 
• In Issue Type, “Equity”.
• In Issue Name, select “Methodhub Software Ltd”.
• Enter your “Application No.” or “PAN No.”
• Click on “I am not a robot”.
• Click “Submit”.

Procedure to Check Methodhub Software Ltd. IPO Allotment Status on Maashitla Securities Pvt. Ltd. (Registrar to the issue)

• Click here to visit the application status page. 
• Select the company. 
• Enter the PAN, application number, and the demat account number. 
• Click on Submit to view the IPO allotment status details.

Methodhub Software Ltd. IPO Details

The Methodhub Software IPO is a book build issue of ₹103.02 crores. It is a combination of a fresh issue of 0.45 crore shares, cumulatively aggregating to ₹87.50 crores and an OFS (offer-for-sale) of 0.08 crore shares. These cumulatively aggregate to ₹15.52 crores.

The price band for the Methodhub Software Ltd. IPO is fixed at ₹190.00 to ₹194.00 per share, with the lot size for applications being 600.

The minimum investment amount for individual (retail) investors is ₹2,32,800.00 (1,200 shares), based on the upper limit. HNIs have a minimum investment threshold of 3 lots or 1,800 shares, cumulatively aggregating to ₹3,49,200.

The booking running lead manager is Horizon Management Pvt. Ltd. and Maashitla Securities Pvt. Ltd is the registrar for the issue. The Market Makers of the company are Giriraj Stock Broking Pvt. Ltd. and Rikhav Securities Ltd. 

Methodhub Software Ltd. IPO Overall Subscription Status

09 December 2025, end of day

Methodhub Software Ltd. saw an overall subscription of 28.91 times as per the BSE data as of December 09, 2025.

 The public issue was subscribed:

• 21.54 times by Retail Individual Investors (RIIs)
• 47.97 times by Non-Institutional Investors (NIIs)
• 27.55 times by Qualified Institutional Buyers (QIBs)

Explore other Upcoming IPOs on BSE and NSE.

Utilisation of Proceeds

The company plans to utilise the net proceeds from the fresh issue towards:

• ₹13.60 crores for repayment/prepayment of certain loans 
• ₹25 crores for long-term working capital needs
• ₹4 crores for investing in the wholly-owned subsidiary named MethodHub Consulting Inc. (USA) for long-term working capital augmentation
• General corporate purposes and unidentified inorganic acquisitions

Check out newly Listed IPOs on BSE and NSE.

About Methodhub Software Ltd.

Methodhub Software Ltd. was founded in 2016 and is an IT services provider offering business solutions to clients across industries such as BFSI, oil and gas/energy, telecom/tech infrastructure, life sciences and healthcare, information technology consulting, and automotive/transportation. Some of its service offerings include data and AI services, ERP/CRM integration, cloud services, IT infrastructure, cybersecurity, and recruitment delivery services.

Financially, the company reported:

• 136% growth in revenues and 113% growth in profit after tax (PAT) between the financial year ending with March 31, 2025 and March 31, 2024
• Assets of ₹122.81 crore as of September 30, 2025, along with total income of ₹80.22 crore by this period. 
• Till the same date, its PAT stood at ₹10.35 crore, along with EBITDA of ₹14.79 crore. 
• Total borrowing stood at ₹39.17 crore as of September 30, 2025. 

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.

To read the RA disclaimer, please click here.